Study of the Prognostic Role of Gene Polymorphism in the Development of B-cell Leukemias and Lymphomas in Children of Kazakh Nationality

March 13, 2023 updated by: Ildar Fakhradiyev, Asfendiyarov Kazakh National Medical University

Preventive and Personalized Medicine (2021-2023)

To search for a genetic marker of B-cell leukemias and lymphomas in children of Kazakh nationality, a single nucleotide polymorphism (SNP) analysis of DNA obtained from the peripheral blood of patients with B-cell leukemias and lymphomas in children of Kazakh nationality and normal control will be performed.

Study Overview

Status

Completed

Conditions

Intervention / Treatment

Study Type

Observational

Enrollment (Actual)

400

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

  • Name: Riza Boranbayeva, PhD
  • Phone Number: +7 727 299 2121
  • Email: riza_brz@mail.ru

Study Contact Backup

Study Locations

  • Kazakhstan
      • Almaty, Kazakhstan
        • Scientific Center of Pediatrics and Pediatric Surgery

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

1 second to 18 years (Child, Adult)

Accepts Healthy Volunteers

N/A

Genders Eligible for Study

All

Sampling Method

Probability Sample

Study Population

Children of the Kazakh population

Description

Inclusion Criteria:

  • ethnicity - Kazakhs in at least three generations
  • active disease or a history of B-line ALL or B-NHL, established on the basis of morphological, cytochemical, immunophenotypic or immunohistochemical research methods with confirmation of the fact of the disease in medical documentation
  • Signed voluntary informed consent of the legal representative to participate in the project

Exclusion Criteria:

  • Children suffering from other types of malignant neoplasms
  • Children with B-linear leukemia and lymphomas with concomitant specified genetic and chromosomal diseases
  • Children of non-Kazakh nationality
  • Absence of signed informed consent or informed refusal of the legal representative to participate in the study before starting therapy

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

Cohorts and Interventions

Group / Cohort
Intervention / Treatment
Experimental group:
children with B-cell leukemia and lymphoma of Kazakhstani nationality
Genetic: SNP analysis of the DNA
SNP analysis of the DNA obtained from peripheral blood sample
Other Names:
  • SNP analysis of the DNA obtained from peripheral blood sample
Control group
children without B-cell leukemia and lymphoma of Kazakhstani nationality
Genetic: SNP analysis of the DNA
SNP analysis of the DNA obtained from peripheral blood sample
Other Names:
  • SNP analysis of the DNA obtained from peripheral blood sample

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Associated with B-cell lymphoma and B-cell acute lymphoblastic leukemia
Time Frame: 1 year
Genotype frequency of SNP in the study genes of participants and control participants.
1 year

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Asfendiyarov Kazakh National Medical University

Investigators

  • Principal Investigator: Riza Boranbayeva, PhD, JSC "Scientific Center of Pediatrics and Pediatric Surgery"

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

April 1, 2022

Primary Completion (Actual)

January 20, 2023

Study Completion (Actual)

January 20, 2023

Study Registration Dates

First Submitted

October 21, 2021

First Submitted That Met QC Criteria

October 26, 2021

First Posted (Actual)

October 27, 2021

Study Record Updates

Last Update Posted (Actual)

March 14, 2023

Last Update Submitted That Met QC Criteria

March 13, 2023

Last Verified

March 1, 2023

More Information

Terms related to this study

Keywords

Additional Relevant MeSH Terms

Other Study ID Numbers

  • 1190

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

UNDECIDED

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Lymphoma

Clinical Trials on SNP analysis of the DNA

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Venezuela

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

3
Subscribe